1-3 of 3
Kiyoshi Mukai, MD
Close
Sort by
Journal Articles

Phase II Study of Chemotherapy (Cx) and Stem Cell Transplantation (SCT) for Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL): Long-Term Follow-up Results of Japan Clinical Oncology Group (JCOG) Study 9402.

Teruhisa Azuma, MD, Kensei Tobinai, MD, PhD, Kunihiko Takeyama, MD, PhD, Taro Shibata, MSc, Haruhiko Fukuda, MD, PhD, Fumio Kawano, MD, PhD, Keiko Aikawa, MD, PhD, Masaharu Kasai, MD, PhD, Takaaki Chou, MD, PhD, Masayuki Sano, MD, PhD, Kuniaki Itoh, MD, PhD, Toshiaki Sai, MD, PhD, Hisashi Yamada, MD, PhD, Kiyoshi Mukai, MD, PhD, Tomomitsu Hotta, MD, PhD, Masanori Shimoyama, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3087.
https://doi.org/10.1182/blood.V114.22.3087.3087
Published: 2009
Journal Articles

Low Serum Total Protein and Unfavorable Pathological Subtype Are Independent Unfavorable Factors in Peripheral T-Cell Lymphoma (PTCL) Treated in Prospective Clinical Tirals; Japan Clinical Oncology Group (JCOG) 0108A Study.

Yoshitoyo Kagami, MD, Tomohiro Kinoshita, MD, Takashi Watanabe, MD, Kuniaki Itoh, MD, Harumi Kaba, MSc, Kenichi Yoshimura, PhD, Motoko Yamaguchi, MD, Mitsutoshi Kurosawa, MD, Kunihiro Tsukasaki, MD, Masaharu Kasai, MD, Kensei Tobinai, MD, Yoshihiro Matsuno, MD, Kiyoshi Mukai, MD, Tomomitsu Hotta, MD, Masanori Shimoyama, MD
Journal: Blood
Blood (2007) 110 (11): 3450.
https://doi.org/10.1182/blood.V110.11.3450.3450
Published: 2007
Journal Articles

Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma.

Tomohiro Kinoshita, MD, Tomomitsu Hotta, MD, Taro Shibata, MSc, Kiyoshi Mukai, MD, Motoko Yamaguchi, MD, Kunihiro Tsukasaki, MD, Yoshitoyo Kagami, MD, Masaharu Kasai, MD, Kensei Tobinai, MD, Masanori Shimoyama, MD
Journal: Blood
Blood (2006) 108 (11): 2465.
https://doi.org/10.1182/blood.V108.11.2465.2465
Published: 2006